Company intelligence / Profile preview

百济医院

Ownership: Private
Employees: ~11000
Development stage: Commercial

Overview

BeiGene has three internally discovered drugs approved globally—BRUKINSA® (BTK inhibitor), tislelizumab/百泽安® (PD‑1 antibody), pamiparib/百汇泽® (PARP inhibitor)—with strong efficacy data supporting global approvals. Over ten additional programs are advancing through clinical development.

Therapeutic areas: Oncology
Modalities: Small moleculesMonoclonal antibodies (mAbs)Targeted therapiesImmuno-oncology agents
Industry: Biotech

Drug pipeline

6 assets

chidamide

Commercial

5 more assets in the full pipeline.

Request access →

Partnerships

Amgen（安进）Novartis（诺华）Bristol Myers Squibb（BMS）EUSA PharmaBio-Thera Solutions

Beyond the preview

Go deeper on 百济医院.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 百济医院.

Explore the full profile